Domain III of the envelope protein as a dengue vaccine target

References

• Guzman MG, Kouri G. Dengue: an update. Lancet Infect. Dis.2(1), 33–42 (2002).
   PubMed Web of Science ®Google Scholar
• Kroeger A, Nathan MB. Dengue: setting the global research agenda. Lancet368(9554), 2193–2195 (2006).
   PubMed Web of Science ®Google Scholar
• Nathan MB, Dayal-Drager R. Recent epidemiological trends, the global strategy and public health advances in dengue. TDR/Scientific Working Group. Geneva, Switzerland, 1–5 October 2006.
   Google Scholar
• Guzman MG, Vazquez S, Kouri G. Dengue: where are we today? Malaysian J. Med. Sciences16(3), 5–12 (2009).
   Google Scholar
• Kuno G. Research on dengue and dengue-like illness in East Asia and the Western Pacific during the first half of the 20th Century. Rev. Med. Virol.17(5), 327–341 (2007).
   PubMedGoogle Scholar
• Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st Century. Trends Microbiol.10(2), 100–103 (2002).
   PubMedGoogle Scholar
• PAHO. Dengue and dengue hemorrhagic fever in the Americas: guidelines for prevention and control. Scientific publication no.548. PAHO, Washington, DC, USA (1994).
   Google Scholar
• Kouri GP, Guzman MG, Bravo JR. Why dengue haemorrhagic fever in Cuba? 2. An integral analysis. Trans. R. Soc. Trop. Med. Hyg.81(5), 821–823 (1987).
   PubMedGoogle Scholar
• Guzman MG, Kouri G. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987–2007. Trans. R. Soc. Trop. Med. Hyg.102(6), 522–523 (2008).
   PubMedGoogle Scholar
• Bravo JR, Guzman MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans. R. Soc. Trop. Med. Hyg.81(5), 816–820 (1987).
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Bravo J et al. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis.6(2), 118–124 (2002).
   PubMedGoogle Scholar
• Halstead SB. Dengue. Lancet370(9599), 1644–1652 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Castro OE, Kouri G et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, dengue 3 epidemic, 2001–2002. Int. J. Infect. Dis.9(5), 280–285 (2005).
   PubMedGoogle Scholar
• Sierra B, García G, Pérez AB et al. Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. Viral Immunol.19(4), 662–668 (2006).
   PubMedGoogle Scholar
• Kou Z, Quinn M, Chen H et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol.80(1), 134–146 (2008).
   PubMed Web of Science ®Google Scholar
• Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcg RIA (CD64) or FcgRIIA (CD32). J. Virol.80(20), 10128–10138 (2006).
   PubMed Web of Science ®Google Scholar
• Kontny U, Kurane I, Ennis FA. g interferon augments Fc g receptor-mediated dengue virus infection of human monocytic cells. J. Virol.62(11), 3928–3933 (1988).
   PubMed Web of Science ®Google Scholar
• Littaua R, Kurane I, Ennis FA. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol.144(8), 3183–3186 (1990).
   PubMed Web of Science ®Google Scholar
• Halstead SB. Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J. Biol. Med.42(5), 350–362 (1970).
   PubMed Web of Science ®Google Scholar
• Halstead SB, Lan NT, Myint TT et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis.8(12), 1474–1479 (2002).
   PubMed Web of Science ®Google Scholar
• Libraty DH, Endy TP, Houng HS et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis.185(9), 1213–1221 (2002).
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis.181(1), 2–9 (2000).
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Duangchinda T, Dejnirattisai W et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J. Immunol.176(6), 3821–3829 (2006).
   PubMed Web of Science ®Google Scholar
• Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J. Virol.80(23), 11418–11431 (2006).
   PubMed Web of Science ®Google Scholar
• Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol. Cell Biol.85(1), 43–45 (2007).
   PubMed Web of Science ®Google Scholar
• Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev. Panam. Salud. Publica21(4), 254–260 (2007).
   PubMed Web of Science ®Google Scholar
• Guzman MG, Mune M, Kouri G. Dengue vaccine: priorities and progress. Expert Rev. Anti Infect. Ther.2(6), 895–911 (2004).
   PubMedGoogle Scholar
• Barrett AD, Hombach J. Opportunities in the development of dengue vaccines. TDR/Scientific Working Group. WHO, Geneva, Switzerland, 1–5 October 2006.
   Google Scholar
• Alvarez M, Rodriguez-Roche R, Bernardo L et al. Dengue hemorrhagic fever caused by sequential dengue 1–3 virus infections over a long time interval: Havana epidemic, 2001–2002. Am. J. Trop. Med. Hyg.75(6), 1113–1117 (2006).
   PubMed Web of Science ®Google Scholar
• Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17–18 November 2005. Vaccine25(21), 4130–4139 (2007).
   PubMed Web of Science ®Google Scholar
• Guzman MG, Kouri G, Valdes L et al. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev. Panam. Salud. Publica11(4), 223–227 (2002).
   PubMedGoogle Scholar
• Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol.79(9), 5516–5528 (2005).
   PubMed Web of Science ®Google Scholar
• Brandler S, Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp. Immunol. Microbiol. Infect Dis.31(2–3), 271–291 (2008).
   PubMedGoogle Scholar
• Guirakhoo F, Kitchener S, Morrison D et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin.2(2), 60–67 (2006).
   PubMed Web of Science ®Google Scholar
• Putnak RJ, Coller BA, Voss G et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine23(35), 4442–4452 (2005).
   PubMedGoogle Scholar
• Sun W, Cunningham D, Wasserman SS et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum. Vaccin.5(1), 33–40 (2009).
   PubMed Web of Science ®Google Scholar
• Velzing J, Groen J, Drouet MT et al. Induction of protective immunity against dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine17(11–12), 1312–1320 (1999).
   PubMedGoogle Scholar
• Apt D, Raviprakash K, Brinkman A et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine24(3), 335–344 (2006).
   PubMedGoogle Scholar
• Blair PJ, Kochel TJ, Raviprakash K et al. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine24(9), 1427–1432 (2006).
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg.66(3), 264–272 (2002).
   PubMed Web of Science ®Google Scholar
• Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J. Virol.80(19), 9577–9585 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang W, Chipman PR, Corver J et al. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol.10(11), 907–912 (2003).
   PubMedGoogle Scholar
• Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature427(6972), 313–319 (2004).
   PubMed Web of Science ®Google Scholar
• Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol.75(16), 7769–7773 (2001).
   PubMed Web of Science ®Google Scholar
• Hung JJ, Hsieh MT, Young MJ et al. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J. Virol.78(1), 378–388 (2004).
   PubMed Web of Science ®Google Scholar
• Chen Y, Maguire T, Hileman RE et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med.3(8), 866–871 (1997).
   PubMed Web of Science ®Google Scholar
• Huerta V, Chinea G, Fleitas N et al. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res.137(2), 225–234 (2008).
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Volpe KE, Squires J et al. Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J. Virol.78(5), 2648–2652 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhn RJ, Zhang W, Rossmann MG et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell108(5), 717–725 (2002).
   PubMed Web of Science ®Google Scholar
• Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect.9(1), 1–6 (2007).
   PubMed Web of Science ®Google Scholar
• Roehrig JT. Antigenic structure of flavivirus proteins. Adv. Virus Res.59, 141–175 (2003).
   PubMed Web of Science ®Google Scholar
• Lok SM, Ng ML, Aaskov J. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J. Med. Virol.65(2), 315–323 (2001).
   PubMed Web of Science ®Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol.15(3), 312–317 (2008).
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology366(2), 349–360 (2007).
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Tadano M, Men R, Lai CJ. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology224(2), 437–445 (1996).
   PubMedGoogle Scholar
• Lin B, Parrish CR, Murray JM, Wright PJ. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology202(2), 885–890 (1994).
   PubMed Web of Science ®Google Scholar
• Zulueta A, Martin J, Hermida L et al. Amino acid changes in the recombinant Dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res.121(1), 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett ND, Barrett AD. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol.82(17), 8828–8837 (2008).
   PubMedGoogle Scholar
• Añez G, Men R, Eckels KH, Lai CJ. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J. Virol.83(20), 10384–10394 (2009).
   PubMedGoogle Scholar
• Megret F, Hugnot JP, Falconar A et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology187(2), 480–491 (1992).
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology246(2), 317–328 (1998).
   PubMed Web of Science ®Google Scholar
• Simmons M, Nelson WM, Wu SJ, Hayes CG. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg.58(5), 655–662 (1998).
   PubMedGoogle Scholar
• Simmons M, Murphy GS, Hayes CG. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg.65(2), 159–161 (2001).
   PubMed Web of Science ®Google Scholar
• Khanam S, Etemad B, Khanna N, Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am. J. Trop. Med. Hyg.74(2), 266–277 (2006).
   PubMed Web of Science ®Google Scholar
• Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology392(1), 103–113 (2009).
   PubMed Web of Science ®Google Scholar
• Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One4(4), e4991 (2009).
   PubMed Web of Science ®Google Scholar
• Fonseca BAL, Khoshnood K, Shope RE, Mason PW. Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli TRPE gene. Am. J. Trop. Med. Hyg.44(5), 500–508 (1991).
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine13(13), 1251–1258 (1995).
   PubMed Web of Science ®Google Scholar
• Simmons M, Murphy GS, Kochel T, Raviprakash K, Hayes CG. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg.65(5), 420–426 (2001).
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Khanna N, Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr. Purif.33(1), 80–91 (2004).
   PubMed Web of Science ®Google Scholar
• Etemad B, Batra G, Raut R et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am. J. Trop. Med. Hyg.79(3), 353–363 (2008).
   PubMed Web of Science ®Google Scholar
• Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine27(43), 6011–6021 (2009).
   PubMed Web of Science ®Google Scholar
• Chen S, Yu M, Jiang T et al. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol.26(6), 361–367 (2007).
   PubMedGoogle Scholar
• Zhang ZS, Yan YS, Weng YW et al. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J. Virol. Methods143(2), 125–131 (2007).
   PubMedGoogle Scholar
• Babu JP, Pattnaik P, Gupta N et al. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine26(36), 4655–4663 (2008).
   PubMed Web of Science ®Google Scholar
• Pattnaik P, Babu JP, Verma SK, Tak V, Rao PV. Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.846(1–2), 184–194 (2007).
   PubMedGoogle Scholar
• Leng CH, Liu SJ, Tsai JP et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect.11(2), 288–295 (2009).
   PubMed Web of Science ®Google Scholar
• Mota J, Acosta M, Argotte R et al. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine23(26), 3469–3476 (2005).
   PubMed Web of Science ®Google Scholar
• Khanam S, Khanna N, Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine24(42–43), 6513–6525 (2006).
   PubMed Web of Science ®Google Scholar
• Khanam S, Rajendra P, Khanna N, Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol.7, 10 (2007).
   PubMedGoogle Scholar
• Brandler S, Lucas-Hourani M, Moris A et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl. Trop. Dis.1(3), e96 (2007).
   PubMed Web of Science ®Google Scholar
• Catteau A, Kalinina O, Wagner MC et al. Dengue virus M protein contains a proapoptotic sequence referred to as ApoptoM. J. Gen. Virol.84(Pt 10), 2781–2793 (2003).
   PubMed Web of Science ®Google Scholar
• Saejung W, Fujiyama K, Takasaki T et al. Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine25(36), 6646–6654 (2007).
   PubMedGoogle Scholar
• Sim AC, Lin W, Tan GK et al. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine26(9), 1145–1154 (2008).
   PubMedGoogle Scholar
• González S, Álvarez A, Caballero E. P64k meningococcal protein as immunological carrier for weak immunogens. Scand. J. Immunol.52(2), 113–116 (2000).
   PubMedGoogle Scholar
• Perez A, Dickinson F, Cinza Z et al. Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol. Appl. Biochem.34(Pt 2), 121–125 (2001).
   PubMed Web of Science ®Google Scholar
• Hermida L, Rodriguez R, Lazo L et al. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods115(1), 41–49 (2004).
   PubMed Web of Science ®Google Scholar
• Hermida L, Rodriguez R, Lazo L et al. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol. Appl. Biochem.39(Pt 1), 107–114 (2004).
   PubMed Web of Science ®Google Scholar
• Zulueta A, Hermida L, Lazo L et al. The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem. Biophys. Res. Commun.308(3), 619–626 (2003).
   PubMedGoogle Scholar
• Hermida L, Bernardo L, Martin J et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine24(16), 3165–3171 (2006).
   PubMed Web of Science ®Google Scholar
• Lazo L, Zulueta A, Hermida L et al. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol. Appl. Biochem.52(Pt 4), 265–271 (2009).
   PubMedGoogle Scholar
• Bernardo L, Izquierdo A, Alvarez M et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res.80(2), 194–199 (2008).
   PubMedGoogle Scholar
• Valdes I, Hermida L, Martin J et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine27(7), 995–1001 (2009).
   PubMedGoogle Scholar
• Izquierdo A, Bernardo L, Martin J et al. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res.138(1–2), 135–138 (2008).
   PubMedGoogle Scholar
• Bernardo L, Hermida L, Martin J et al. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch. Virol.153(5), 849–854 (2008).
   PubMedGoogle Scholar
• Valdés I, Hermida L, Gil L et al. Heterologous prime–boost strategy in nonhuman primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int. J. Infect. Dis. DOI: 10.1016/j.ijid.2009.06.017 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Sabchareon A, Lang J, Chanthavanich P et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr. Infect. Dis. J.23(2), 99–109 (2004).
   PubMed Web of Science ®Google Scholar
• Simasathien S, Thomas SJ, Watanaveeradej V et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am. J. Trop. Med. Hyg.78(3), 426–433 (2008).
   PubMed Web of Science ®Google Scholar
• Guy B, Nougarede N, Begue S et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine26(45), 5712–5721 (2008).
   PubMed Web of Science ®Google Scholar
• Lazo L, Hermida L, Zulueta A et al. A recombinant capsid protein from dengue-2 induces protection in mice against homologous virus. Vaccine25(6), 1064–1070 (2007).
   PubMed Web of Science ®Google Scholar
• Gil L, López C, Lazo L et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int. Immunol.21(10), 1175–1183 (2009).
   PubMed Web of Science ®Google Scholar
• Valdés I, Bernardo L, Gil L et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology394(2), 249–258 (2009).
   PubMed Web of Science ®Google Scholar